177 related articles for article (PubMed ID: 15962500)
1. Systemic adverse effects of topical ocular treatments.
Labetoulle M; Frau E; Le Jeunne C
Presse Med; 2005 Apr; 34(8):589-95. PubMed ID: 15962500
[TBL] [Abstract][Full Text] [Related]
2. [New aspects on systemic adverse effects of ocular drugs].
Uusitalo H; Salminen L
Duodecim; 1998; 114(3):287-92. PubMed ID: 10895504
[No Abstract] [Full Text] [Related]
3. The unwanted ocular effects from topical ophthalmic drugs. Their occurrence, avoidance and reversal.
Lyle WM; Hopkins GA
J Am Optom Assoc; 1977 Dec; 48(12):1519-23. PubMed ID: 599247
[TBL] [Abstract][Full Text] [Related]
4. Ophthalmic drug dosage forms: characterisation and research methods.
Baranowski P; Karolewicz B; Gajda M; Pluta J
ScientificWorldJournal; 2014; 2014():861904. PubMed ID: 24772038
[TBL] [Abstract][Full Text] [Related]
5. Systemic adverse effects of topical ophthalmic agents. Implications for older patients.
Diamond JP
Drugs Aging; 1997 Nov; 11(5):352-60. PubMed ID: 9359022
[TBL] [Abstract][Full Text] [Related]
6. [General complications after local pharmacological ophthalmological treatment].
Milkowski S
Wiad Lek; 1968 Dec; 21(23):2127-32. PubMed ID: 4884996
[No Abstract] [Full Text] [Related]
7. [Bioavailability of drugs applied to the eye externally].
Sieradzki E
Klin Oczna; 1991 Jan; 93(1):34-6. PubMed ID: 2046287
[TBL] [Abstract][Full Text] [Related]
8. How ophthalmic drugs can fool you.
Wong EK; Wang S; Leopold IH
RN; 1980 Mar; 43(3):36-44. PubMed ID: 6899383
[No Abstract] [Full Text] [Related]
9. Review of ocular drug delivery.
Sultana Y; Jain R; Aqil M; Ali A
Curr Drug Deliv; 2006 Apr; 3(2):207-17. PubMed ID: 16611007
[TBL] [Abstract][Full Text] [Related]
10. Ocular preparations: the formulation approach.
Kaur IP; Kanwar M
Drug Dev Ind Pharm; 2002 May; 28(5):473-93. PubMed ID: 12098838
[TBL] [Abstract][Full Text] [Related]
11. Minimizing systemic absorption of topically administered ophthalmic drugs.
Urtti A; Salminen L
Surv Ophthalmol; 1993; 37(6):435-56. PubMed ID: 8100087
[TBL] [Abstract][Full Text] [Related]
12. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review.
Gaynes BI; Fiscella R
Drug Saf; 2002; 25(4):233-50. PubMed ID: 11994027
[TBL] [Abstract][Full Text] [Related]
13. Systemic bioavailability of ocularly applied 1% atropine eyedrops.
Kaila T; Korte JM; Saari KM
Acta Ophthalmol Scand; 1999 Apr; 77(2):193-6. PubMed ID: 10321537
[TBL] [Abstract][Full Text] [Related]
14. Aqueous formulations and ointments.
MacKeen DL
Int Ophthalmol Clin; 1980; 20(3):79-92. PubMed ID: 6998903
[TBL] [Abstract][Full Text] [Related]
15. [Drug side effects on the eye and systemic side effects of medicamentous ophthalmologic therapy].
Teichmann KD
Ther Umsch; 1990 Apr; 47(4):289-97. PubMed ID: 2191462
[TBL] [Abstract][Full Text] [Related]
16. CLINICAL EVALUATION OF A NEW MYDRIATIC-MYDRILATE.
Cowan EC; Archer D
Br J Ophthalmol; 1962 Dec; 46(12):730-6. PubMed ID: 18170843
[No Abstract] [Full Text] [Related]
17. [Corticosteroids and ophthalmology].
Girard B
Rev Prat; 1990 Feb; 40(6):536-40. PubMed ID: 2320879
[TBL] [Abstract][Full Text] [Related]
18. Fatal necrotising enterocolitis due to mydriatic eye drops.
Ozgun U; Demet T; Ozge KA; Zafer D; Murat S; Mehmet Y; Nilgun K
J Coll Physicians Surg Pak; 2014 May; 24 Suppl 2():S147-9. PubMed ID: 24906272
[TBL] [Abstract][Full Text] [Related]
19. Systemic toxicity. Associated with topical ophthalmic medications.
Flach AJ
J Fla Med Assoc; 1994 Apr; 81(4):256-60. PubMed ID: 8046365
[TBL] [Abstract][Full Text] [Related]
20. Ocular therapeutics.
Jeglum EL
Nurs Clin North Am; 1981; 16(3):453-77. PubMed ID: 6117832
[No Abstract] [Full Text] [Related]
[Next] [New Search]
